This news release was originally published on the Department of Defense's website.

The Department of Health and Human Services and the Department of Defense announced the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic, to be delivered in the first half of 2021 to treat non-hospitalized, high-risk COVID-19 patients.